Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Biotech
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Nick Paul Taylor
Aug 28, 2026 9:17am
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Aug 28, 2026 4:30am
CEPI pushes Egyptian biotech's Ebola vaccine toward clinic
Aug 27, 2026 10:10am
Osivax bags flu vaccine rights to pursue combination shot vision
Aug 27, 2026 10:00am
ProFound forms $35M preeclampsia pact with Gates Foundation
Aug 27, 2026 6:30am
Fierce Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Aug 26, 2026 11:30am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma